
According to Benzinga Pro data, during Q4, NGM Biopharmaceuticals (NASDAQ:NGM) posted sales of $20.96 million. Earnings were up 5.65%, but NGM Biopharmaceuticals still reported an overall loss of $27.23 million. NGM Biopharmaceuticals collected $18.57 million in revenue during Q3, but reported earnings showed a $28.86 million loss.